Gates Foundation backs Blue Lake's RSV vaccine with $5M grant
What's the deal? Blue Lake BiotechnologyDealroom has a profile for this one. Try Dealroom → has secured a $5 million grant from the Gates FoundationDealroom has a profile for this one. Try Dealroom → to expand its ongoing Phase 1/2a pediatric trial of BLB201, an intranasal vaccine candidate against respiratory syncytial virus (RSV). The funding will widen enrollment to children as young as 12 months.
Why now? A separate committee reviewed unblinded interim data through April 2026, after which the FDA cleared Blue Lake to enroll toddlers from 12 months old. The expanded study runs through the 2026-2027 RSV season.
What's the endgame? BLB201 encodes the RSV F protein and uses a proprietary PIV5 vector not known to cause human disease. The money funds a larger safety and efficacy dataset and will also test whether the vaccine can reduce RSV transmission within families.
The grant lands in the top 10% of all-time US health grants by size, according to funding data covering 7,086 comparable rounds. Early data showed preliminary efficacy above 70% in preventing symptomatic RSV in a study population of 111.
What could go wrong? The trial remains blinded and is assessing safety and immune response, so efficacy is not yet established. BLB201 would also compete with maternal vaccines and long-acting antibodies such as Beyfortus and Merck's Enflonsia, meaning it must show a clear advantage to stand out.
RSV infects more than 64 million people worldwide each year. In the US, it hospitalises up to 80,000 children under five and causes up to 10,000 deaths annually, yet no RSV vaccine is licensed for universal use in infants and young children.
“This timely grant gives Blue Lake the ability to expand our ongoing clinical study of our RSV vaccine candidate with a focus on toddlers as young as 12 months old,” said chief executive officer Biao He.
The signal: The grant signals growing interest in intranasal delivery as a differentiator in a crowded RSV field. But it mainly buys more testing — not a near-term market entrant.
Read more: markets.financialcontent.com
Image credit: Blue Lake Biotechnology
